Highlights Newsletter 4
This newsletter presents you the following key sessions:
2. Metformin does not improve breast cancer outcomes in moderate- to high-risk breast cancer
3. Clinical utility of genomic profiling in patients with metastatic breast cancer
5. The prognostic and predictive value of intrinsic subtype across the MONALEESA-2, -3, and -7 studies